COMMUNIQUÉS West-GlobeNewswire

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer
29/01/2024
Project to test combination of TransCode’s proprietary TTX delivery platform and Debiopharm’s drug delivery technologies BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA [...]
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
29/01/2024
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Privia Health Appoints Edward C. Fargis as General Counsel
29/01/2024
ARLINGTON, Va., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that Edward C. Fargis has been named Executive Vice President, General Counsel and Corporate Secretary, effective [...]
Sirona Biochem Announces Loan
29/01/2024
VANCOUVER, British Columbia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ” or the “ Company ”) announced that it has entered into a demand grid promissory note [...]
New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors
29/01/2024
COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, [...]
Leading UK Timber Processor and Packaging Manufacturer, James Jones & Sons Ltd., Adopts Intelligent Bio Solutions’ Fingerprint Drug Screening System Across its 25 Sites and 1,300 Employees
29/01/2024
Intelligent Fingerprinting to be used for in-house drug testing, enabling full testing control to support new James Jones drug and alcohol testing policy Portable Intelligent Fingerprinting system easily covers testing [...]
PetMed Express, Inc. Sets Fiscal Third Quarter 2024 Earnings Call
29/01/2024
DELRAY BEACH, Fla., Jan. 29, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (Nasdaq: PETS) (the “Company”), Your Trusted Pet Health Expert TM will hold a conference call on Thursday, February 8, 2024 at 4:30pm Eastern [...]
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
29/01/2024
– Preclinical data demonstrated PALI-2108 to be safe and well tolerated – PALI-2108 is orally delivered and colon activated allowing for local activity with low systemic exposure – Company advancing PALI-2108 for the [...]
Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ
29/01/2024
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc [...]
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
29/01/2024
HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights to HB-700 program [...]
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
29/01/2024
WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a [...]
Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024
29/01/2024
SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its [...]
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
29/01/2024
Novel steroid-free topical foam effectively controls seborrheic dermatitis Once-daily ZORYVE ® (roflumilast) topical foam, 0.3%, is approved to treat seborrheic dermatitis in individuals 9 years of age and older [...]
Carmot Therapeutics Announces Completion of Acquisition by Roche
29/01/2024
BERKELEY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases [...]
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward
29/01/2024
Lifeward brand reflects the Company’s commitment to pioneering innovative technology to empower the pursuit of life’s ambitions in the face of physical limitation or disability The complete rebrand includes new name, [...]
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
29/01/2024
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and [...]
OneMedNet Announces Participation as an Exhibitor at the 15ᵗʰ Annual SCOPE Summit
29/01/2024
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), the leading curator of regulatory-grade imaging Real World Data (“iRWD”), today announced its [...]
ProSomnus Poised to Support Obstructive Sleep Apnea Patients Following Discontinuation of Philips Respironics OSA Devices
29/01/2024
PLEASANTON, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA ) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced that the company is well-positioned to support [...]
4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden
29/01/2024
Initial interim landmark data analysis (N=50 at 24 Weeks) will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024 [...]

Pages